Following launch of next-generation medical drone, Everdrone CEO Mats Sällström on 2026

After completing development of the new drone, E3, Everdrone enters 2026 with a full focus on operational deployment and demonstrating real-world impact.

“During 2026, our focus will be on deploying E3, conducting a new clinical study, and continuing to expand our operational presence in Sweden and across Europe,” says Mats Sällström, CEO of Everdrone.

The first months of the year have been dedicated to finalizing Everdrone’s new-generation drone, E3 – a platform that marks the beginning of the company’s commercial phase.

“The new drone will be gradually deployed in the areas and regions where we are already active, and introduced in new operational areas with clear medical potential.”

Everdrone will shortly initiate a new clinical study in collaboration with Karolinska Institutet. The study will be conducted in an operational environment and aims to systematically assess the medical impact of drone-assisted emergency care.

“Combining operational rollout with clinical evaluation is a central part of our long-term strategy and strengthens the medical evidence for our service.”

At the same time, international expansion continues. Operations have already been launched in France, and regulatory work is ongoing in the UK, paving the way for further market entries.

With the new E3 drone in place, regulatory frameworks secured, and clinical research about to begin, Everdrone’s focus in 2026 is to move from proof of concept to demonstrated societal impact.

“2026 is the year we take the next step – from innovation to becoming an established part of emergency healthcare,” says Mats Sällström, CEO of Everdrone.